References
- Chenoweth D E. Complement activation produced by biomaterials. Trans Am Soc Artif Intern Organ 1986; 32: 226–32
- Tamiya T, Yamosaki M, Maeo Y, Yamashiro T, Qgoshi S, Fuiimoto S. Complement activation in cardiopulmonary bypass, with special reference to anaphylatoxin production in membrane and bubble oxygenators. Ann Thoracic Surg 1988; 46: 47–57
- Videm V, Fosse E, Mollnes T E, Garred P, Svennevig J L. Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting. Ann Thoracic Surg 1990; 50: 387–91
- Gillinov A M, Devaleria P A, Winkelstein J A, et al. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thoracic Surg 1993; 55: 619–24
- Kirklin J K, Westaby S, Blackstone E H, Kirklin J W, Chenoweth D E, Pacifico A D. Complement and damaging effects of cardiopulmonary bypass. J Thoracic Cardiovasc Surg 1983; 86: 845–57
- Michie H R, Monague K R, Sprigg D R, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481–6
- Tracey K J, Lowry S F, Fahey T J, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987; 164: 415–22
- Andersen L W, Baek L, Degn H, et al. Presence of circulating endotoxin during cardiac operations. J Thoracic Cardiovasc Surg 1987; 93: 115–19
- Casey W F, Gabriel H J, Hannallah R S, Midgley F M, Kahn N W. Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgery. Crit C Med 1992; 20: 1091–6
- Cavaillon J M, Fitting C, Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990; 20: 253–7
- Wolff M S. Biological effects of bacterial endotoxins in man. J Infect Dis 1973; 129(Suppl)259–64
- Corrigan J J, Walker L R, May N. Changes in blood coagulation system associated with septicemia. N Engl J Med 1968; 279: 851–6
- Zimmermann J J, Dietrich K A. Current perspectives on septic shock. Pediatr Clin North Am 1987; 34: 131–64
- Kushner J, Ganapathi M, Schultz D. The acute phase response is mediated by heterogenous mechanisms. Ann NY Acad Sci 1989; 557: 19–30
- Cruickshank A M, Fraser W D, Burns H JG, Van Damme J, Shenikin A. Response of serum interleukin-b in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79: 161–5
- Morgan D A, Ruscetti F W, Gallo R C. Selection in vitro of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007–8
- Paul J L, Russelo C W, Planisek J A, et al. Studies of growth promoting lymphokine interleukin 2. J Immunol Methods 1982; 50: 173–8
- Loctsher H, Steinmetz H, Lesslauer W. Tumor necrosis factor: receptors and inhibitors. Cancer Cells 1991; 3: 221–6
- Haeffner-Cavallion N, Rousseller N, Ponzio O, et al, Induction of interleukin-1 production in